

## USER FEE OBLIGATIONS

User fees are expended only for costs necessary to support human generic drug activities as defined in GDUFA. Included and excluded costs for this function are described in Appendix D of this report.

In FY 2013, FDA obligated \$121,280,100 from human generic drug user fees. Table 2 provides a breakout of user fee obligations by expense category during FY 2013.

**TABLE 2: HUMAN GENERIC DRUG USER FEE  
OBLIGATIONS BY EXPENSE CATEGORY AS OF SEPTEMBER 30, 2013**

EXPENSE CATEGORY	FY 2013
Personnel Compensation and Benefits	\$17,521,912
Travel and Transportation	\$300,651
Rent	\$5,006,000
Communications	\$1,150,752
Contract Services	\$80,516,066
Equipment and Supplies	\$8,125,627
Other <sup>2</sup>	\$8,659,092
<b>TOTAL OBLIGATIONS</b>	<b>\$121,280,100</b>

<sup>2</sup> Other includes expenses from categories such as rent payments to others, printing & reproduction, and other miscellaneous expenses.

In FY 2013, FDA initiated many new contract initiatives in order to implement the new GDUFA organizational structure and program. These initiatives included developing advanced statistical methods for pharmacy compounding and new pharmacokinetic drug products, business process improvements, purchase of specialized lab equipment, program management, and other program start-up costs.